-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
-
-
-
-
-
-
Corcept loses patent appeal against Teva over generic Korlym
-
-
-
-
-
-
-
Teva Pharma (TEVA) call put ratio 3.4 calls to 1 put into quarter results
-
-
-
-
-
-
-
Jefferies just introduced this pharma stock as a top 2026 idea
-
-
-
-
-
-
-
Teva receives European approvals for two denosumab biosimilars
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Teva Pharma (TEVA)
-
413,396 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

